drugset / Trial / NCT06070597

A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety

NCT06070597

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

This study aims to evaluate the effects of iclepertin in the range of therapeutic to supra-therapeutic exposures on the (QT/QTc): Electrocardiogram (ECG) time interval from the start of the QRS complex (ECG time interval) to the end of the T wave / QT interval corrected for heart rate, e.g. using the method of Fridericia or Bazett interval and other ECG parameters.

Timeline

Start
2024-01-25
Primary completion
2024-06-05
Completion
2024-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Iclepertin Small molecule Oral
Subject Moxifloxacin Small molecule

Indications

No indication recorded.